. Author manuscript; available in PMC: 2008 Dec 1.

Published in final edited form as: Biol Blood Marrow Transplant. 2007 Dec;13(12):1499–1507. doi: 10.1016/j.bbmt.2007.09.004

Table 2.

Multivariate analysis of transplant outcomes among 405 patients following nonmyeloablative HCT

	N	Overall mortality		Non-relapse mortality		Relapse / progression
	N	HR (95% CI)	P-value	HR (95% CI)	P-value	HR (95% CI)	P-value
Donor:
MRD	221	1.0	0.95	1.0	0.93	1.0	0.60
URD	184	1.01 (0.7-1.4)	0.95	0.98 (0.6-1.6)	0.93	1.10 (0.8-1.6)	0.60
Comorbidity category: [34]
HCT-CI 0	105	1.0	<0.0001	1.0	<0.0001	1.0	0.52
HCT-CI 1-2	126	1.61 (1.0-2.5)		1.89 (0.9-3.9)		1.20 (0.8-1.8)
HCT-CI ≥3	174	2.65 (1.8-4.0)		3.93 (2.0-7.7)		1.25 (0.8-1.9)
Relapse risk category: [35]
Low	88	1.0	<0.0001	1.0	0.05	1.0	<0.0001
Intermediate	194	1.31 (0.9-2.0)		0.76 (0.4-1.3)		1.82 (1.1-2.9)
High	123	2.94 (1.9-4.5)		1.46 (0.8-2.5)		3.80 (2.3-6.2)
Age at transplant:
<50	136	1.0	0.04	1.0	0.06	1.0	0.83
≥50	239	1.38 (1.0-1.9)	0.04	1.61 (1.0-2.7)	0.06	1.04 (0.7-1.4)	0.83
Sex mismatch:
No	208	1.0	0.02	1.0	0.03	1.0	0.10
Yes	197	1.39 (1.0-1.8)	0.02	1.64 (1.1-2.5)	0.03	1.29 (1.0-1.8)	0.10
Stem cell source:
PBSC	397	1.0	0.53	1.0	0.96	1.0	0.28
BM	8	1.36 (0.5-3.4)	0.53	0.96 (0.2-4.1)	0.96	1.86 (0.7-5.2)	0.28
Patient CMV status:
Neg	180	1.0	0.16	1.0	0.02	1.0	0.29
Pos	225	1.23 (0.9-1.6)	0.16	1.71 (1.1-2.7)	0.02	1.19 (0.9-1.6)	0.29
Fludarabine in preparative regimen:
Yes	316	1.0	0.20	1.0	0.64	1.0	0.95
No	89	0.76 (0.5-1.2)	0.20	0.86 (0.4-1.6)	0.64	0.99 (0.6-1.5)	0.95

HR denotes hazard ratio; CI, confidence interval; MRD, HLA-identical sibling donor; URD, HLA-matched unrelated donor; HCT-CI, hematopoietic cell transplantation comorbidity index; PBSC, peripheral blood stem cells; BM, bone marrow; CMV, cytomegalovirus.